Pharmacokinetics of sildenafil and its metabolite, N-desmethylsildenafil, in rats with liver cirrhosis and diabetes mellitus, alone and in combination

Xenobiotica

Volumn 41, Issue 2, 2011, Pages 164-174

  Ahn, C Y ^a,b   Bae, S K ^c   Bae, S H ^a   Kang, H E ^c   Kim, S H ^d   Lee, M G ^c   Shin, W G ^a  

^a Seoul National University   (South Korea)

^b National Institute of Food and Drug Safety Evaluation   (South Korea)

^c The Catholic University of Korea   (South Korea)

^d Gangneung Wonju National University   (South Korea)

Author keywords

Hepatic and intestinal CYP2C11 and 3A subfamily; Pharmacokinetics; Rats with liver cirrhosis and or diabetes mellitus; Sildenafil and N desmethylsildenafil

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 2B1; CYTOCHROME P450 2B2; CYTOCHROME P450 2C11; CYTOCHROME P450 2E1; CYTOCHROME P450 3A; DRUG METABOLITE; N DESMETHYLSILDENAFIL; SILDENAFIL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG PROTEIN BINDING; HUMAN; IMMUNOBLOTTING; LIQUID CHROMATOGRAPHY; LIVER CIRRHOSIS; LIVER CLEARANCE; LIVER MICROSOME; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; TANDEM MASS SPECTROMETRY;

ADMINISTRATION, ORAL; ANIMALS; BLOOD PROTEINS; CYTOCHROME P-450 ENZYME SYSTEM; DIABETES MELLITUS, EXPERIMENTAL; HUMANS; IMMUNOBLOTTING; INJECTIONS, INTRAVENOUS; INTESTINES; LIVER CIRRHOSIS; MALE; MICROSOMES, LIVER; PIPERAZINES; PROTEIN BINDING; PURINES; RATS; RATS, SPRAGUE-DAWLEY; SULFONES; VASODILATOR AGENTS;

RATTUS;

EID: 78651367391     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2010.532885     Document Type: Article

References (44)

1. Ackerman DM, Leibman KC (1977). Efect of experimental diabetes on drug metabolism in the rat. Drug Metab Dispos 5:405-410.
2. Ahn CY, Bae SK, Bae SH, Kim T, Jung YS, Kim YC, Lee MG, Shin WG. (2009). Pharmacokinetics of oltipraz in diabetic rats with liver cirrhosis. Br J Pharmacol 156:1019-1028.
3. Ahn CY Bae SK, Jung YS, Lee I, Kim YC, Lee MG, Shin WG. (2008). Pharmacokinetic parameters of chlorzoxazone and its main metabolite, 6-hydroxychlorzoxazone, after intravenous and oral administration of chlorzoxazone to liver cirrhotic rats with diabetes mellitus. Drug Metab Dispos 36:1233-1241.
4. Bae SH, Bae SK, Lee MG. (2009). Efect of hepatic CYP inhibitors on the metabolism of sildenafl and formation of its metabolite, N-desmethylsildenafl, in rats in vitro and in vivo. J Pharm Pharmacol 61:1637-1642.
5. Bae SK, Lee SJ, Lee JY Lee Y Lee I, Kim SG, Lee MG. (2004). Pharmacokinetic changes of oltipraz after intravenous and oral administration to rats with liver cirrhosis induced by dimethylnitrosamine. Int J Pharm 275:227-238. (Pubitemid 38481535)
6. Barnett CR, Gibson GG, Wolf CR, Flatt PR, Ioannides C. (1990). Induction of cytochrome P450III and P450IV family proteins in streptozotocin-induced diabetes. Biochem J 268:765-769.
7. Boudinot FD, Jusko WJ. (1984). Fluid shifts and other factors afecting plasma protein binding of prednisolone by equilibrium dialysis. J Pharm Sci 73:774-780.
8. Bradford MM. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
9. Chiou WL. (1978). Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve. J Pharmacokinet Biopharm 6:539-546.
10. Choi YH, Lee DC, Lee I, Lee MG. (2008). Changes in metformin pharmacokinetics after intravenous and oral administration to rats with short-term and long-term diabetes induced by streptozotocin. J Pharm Sci 97:5363-5375.
11. Duggleby RG. (1995). Analysis of enzyme progress curves by nonlinear regression. Meth Enzymol 249:61-90.
12. George J, Liddle C, Murray M, Byth K, Farrell GC (1995). Pre-translational regulation of cytochrome P450 genes is responsible for disease-specifc changes of individual P450 enzymes among patients with cirrhosis. Biochem Pharmacol 49:873-881.
13. George J, Rao KR, Stern R, Chandrakasan G. (2001). Dimethylnitrosamine- induced liver injury in rats: the early deposition of collagen. Toxicology 156:129-138
14. Gibaldi M, Perrier D (Eds.). (1982). Pharmacokinetics (2nd ed.). New York: Marcel-Dekker.
15. Goeting NL, Fleming JS, Gallagher P, Walmsely BH, Karran SJ. (1986). Alterations in liver blood fow and reticuloendothelial function in progressive cirrhosis in the rat. J Nucl Med 27:1751-1754.
16. Horiike N, Abe M, Kumagi T, Hiasa Y, Akbar SM, Michitaka K, Onji M. (2005). Te quantifcation of cytochrome P-450 (CYP 3A4) mRNA in the blood of patients with viral liver diseases. Clin Biochem 38:531-534.
17. Ioannides C. (1996). Expression of cytochrome P450 protein in disease. In: Cytochrome P450. Metabolic and Toxicological Aspects (Chapter 12). Boca Raton, FL: CRC Press, pp. 301-327.
18. Jézéquel AM, Mancini R, Rinaldesi ML, Macarri G, Venturini C, Orlandi F. (1987). A morphological study of the early stages of hepatic fbrosis induced by low doses of dimethylnitrosamine in the rat. J Hepatol 5:174-181.
19. Kang KW, Kim YG, Cho MK, Bae SK, Kim CW, Lee MG, Kim SG. (2002). Oltipraz regenerates cirrhotic liver through CCAAT/enhancer binding protein-mediated stellate cell inactivation. FASEB J 16:1988-1990.
20. Kim SH, Choi YM, Lee MG. (1993). Pharmacokinetics and pharmacodynamics of furosemide in protein-calorie malnutrition. J Pharmacokinet Biopharm 21:1-17.
21. Kim YC, Lee AK, Lee JH, Lee I, Lee DC, Kim SH, Kim SG, Lee MG. (2005). Pharmacokinetics of theophylline in diabetes mellitus rats: induction of CYP1A2 and CYP2E1 on 1,3-dimethyluric acid formation. Eur J Pharm Sci 26:114-123.
22. Kwon SY (2003). [Prevalence and clinical signifcance of diabetes mellitus in patients with liver cirrhosis]. Taehan Kan Hakhoe Chi 9:205-211.
23. Lee JH, Lee MG. (2008). Telithromycin pharmacokinetics in rat model of diabetes mellitus induced by alloxan or streptozotocin. Pharm Res 25:1915-1924.
24. Lee MG, Chiou WL. (1983). Evaluation of potential causes for the incomplete bioavailability of furosemide: gastric frst-pass metabolism. J Pharmacokinet Biopharm 11:623-640.
25. Matzke GR, Frye RF, Early JJ, Straka RJ, Carson SW. (2000). Evaluation of the infuence of diabetes mellitus on antipyrine metabolism and CYP1A2 and CYP2D6 activity. Pharmacotherapy 20:182-190.
26. Mitruka BM, Rawnsley HM (Eds.). (1981). Clinical, Biochemical and Hematological Reference Values in Normal Experimental Animals and Normal Humans (2nd ed.). New York: Masson Publishing.
27. Moscatiello S, Manini R, Marchesini G. (2007). Diabetes and liver disease: an ominous association. Nutr Metab Cardiovasc Dis 17:63-70.
28. Muirhead GJ, Wilner K, Colburn W, Haug-Pihale G, Rouviex B. (2002). Te efects of age and renal and hepatic impairment on the pharmacokinetics of sildenafl. Br J Clin Pharmacol 53(Suppl. 1):21S-30S.
29. Musicki B, Burnett AL. (2007). Endothelial dysfunction in diabetic erectile dysfunction. Int J Impot Res 19:129-138.
30. Nam BH, Sohn DH, Ko G, Kim JB. (1997). Efect of hepatic cirrhosis on the pharmacokinetics of theophylline in rats. Arch Pharm Res 20:318-323.
31. Ohara K, Kusano M. (2002). Anti-transforming growth factor-beta1 antibody improves survival rate following partial hepatectomy in cirrhotic rats. Hepatol Res 24:174-183.
32. Øie S, Guentert TW. (1982). Comparison of equilibrium time in dialysis experiments using spiked plasma or spiked bufer. J Pharm Sci. 71. 127-128.
33. Reinke LA, Stohs SJ, Rosenberg H. (1978). Altered activity of hepatic mixed-function mono-oxygenase enzymes in streptozotocin-induced diabetic rats. Xenobiotica 8:611-619.
34. Sato H, Terasaki T, Okumura K, Tsuji A. (1991). Efect of receptor up-regulation on insulin pharmacokinetics in streptozotocin-treated diabetic rats. Pharm Res 8:563-569.
35. Shim HJ, Lee EJ, Kim SH, Kim SH, Yoo M, Kwon JW, Kim WB, Lee MG. (2000). Factors infuencing the protein binding of a new phosphodiesterase V inhibitor, DA-8159, using an equilibrium dialysis technique. Biopharm Drug Dispos 21:285-291.
36. Shin HS, Bae SK, Lee MG. (2006). Pharmacokinetics of sildenafl after intravenous and oral administration in rats: hepatic and intestinal frst-pass efects. Int J Pharm 320:64-70.
37. Sotaniemi EA, Pelkonen O, Arranto AJ, Tapanainen P, Rautio A, Pasanen M. (2002). Diabetes and elimination of antipyrine in man: an analysis of 298 patients classifed by type of diabetes, age, sex, duration of disease and liver involvement. Pharmacol Toxicol 90:155-160.
38. Tummel KE, Schenkman JB. (1990). Efects of testosterone and growth hormone treatment on hepatic microsomal P450 expression in the diabetic rat. Mol Pharmacol 37:119-129.
39. Toda K, Miwa Y, Kuriyama S, Fukushima H, Shiraki M, Murakami N, Shimazaki M, Ito Y, Nakamura T, Sugihara J, Tomita E, Nagata C, Suzuki K, Moriwaki H. (2005). Erectile dysfunction in patients with chronic viral liver disease: its relevance to protein malnutrition. J Gastroenterol 40:894-900.
40. Vidal J, Ferrer JP, Esmatjes E, Salmeron JM, González-Clemente JM, Gomis R, Rodés J. (1994). Diabetes mellitus in patients with liver cirrhosis. Diabetes Res Clin Pract 25:19-25.
41. Walker DK, Ackland MJ, James GC, Muirhead GJ, Rance DJ, Wastall P, Wright PA. (1999). Pharmacokinetics and metabolism of sildenafl in mouse, rat, rabbit, dog and man. Xenobiotica 29:297-310.
42. Wang Y, Chow MS, Zuo Z. (2008). Mechanistic analysis of pH-dependent solubility and trans-membrane permeability of amphoteric compounds: application to sildenafl. Int J Pharm 352: 217-224.
43. Wang Z, Hall SD, Maya J F, Li L, Asghar A, Gorski JC (2003). Diabetes mellitus increases the in vivo activity of cytochrome P450 2E1 in humans. Br J Clin Pharmacol 55:77-85.
44. Wilkinson GR, Shand DG. (1975). A physiological approach to hepatic drug clearance. Clin Pharmacol Ter 18:377-390.